Careers
Abcuro is a clinical-stage biotechnology company developing antibody-based therapies for autoimmune diseases and cancer. The company focuses on targeting highly cytotoxic T cells that contribute to tissue damage and disease progression. Its pipeline includes ulviprubart, a monoclonal antibody designed to selectively deplete cytotoxic T cells while preserving other immune cells. Abcuro is evaluating its therapies in clinical studies for conditions including inclusion body myositis and other immune-mediated diseases, as well as potential applications in oncology.